These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 28207137)

  • 1. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Ravents CX; Cataln R; Revents J
    Int J Biol Markers; 2005; 20(2):119-222. PubMed ID: 28207137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Int J Biol Markers; 2005; 20(2):119-22. PubMed ID: 16011042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
    Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
    J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy.
    von Klot CA; Kuczyk MA; Boeker A; Reuter C; Imkamp F; Herrmann TR; Tezval H; Kramer MW; Perner S; Merseburger AS
    Oncol Lett; 2017 Jan; 13(1):22-28. PubMed ID: 28123517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
    Wang Y; Dai B; Ye DW
    Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
    Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
    Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum total and free testosterone level of Japanese men: a population-based study.
    Okamura K; Ando F; Shimokata H
    Int J Urol; 2005 Sep; 12(9):810-4. PubMed ID: 16201977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
    Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
    Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigative clinical study on prostate cancer part IV: exploring functional relationships of total testosterone predicting free testosterone and total prostate-specific antigen in operated prostate cancer patients.
    Porcaro AB; Petrozziello A; Migliorini F; Lacola V; Romano M; Sava T; Ghimenton C; Caruso B; Zecchini Antoniolli S; Rubilotta E; Monaco C; Comunale L
    Urol Int; 2011; 86(4):399-406. PubMed ID: 21508618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
    Porcaro AB; Ghimenton C; Petrozziello A; Sava T; Migliorini F; Romano M; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C
    Anticancer Res; 2012 Oct; 32(10):4523-32. PubMed ID: 23060581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
    Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
    Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low levels of serum testosterone in middle-aged men impact pathological features of prostate cancer.
    Llukani E; Katz BF; Agalliu I; Lightfoot A; Yu SS; Kathrins M; Lee Z; Su YK; Monahan Agnew K; McGill A; Eun DD; Lee DI
    Prostate Int; 2017 Mar; 5(1):17-23. PubMed ID: 28352619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
    Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
    Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in prostate cancer patients taking androgen deprivation therapy.
    Dacal K; Sereika SM; Greenspan SL
    J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between serum total testosterone and free testosterone levels with serum hemoglobin and hematocrit levels: a study in 1221 men.
    Shin YS; You JH; Cha JS; Park JK
    Aging Male; 2016 Dec; 19(4):209-214. PubMed ID: 27750487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.